கட்டி ஆராய்ச்சி இதழ்
திறந்த அணுகல்

சுருக்கம்

Immunotherapy, The New Frontier Cancer

Daniela Capdepon

Some cancers are very sensitive to chemotherapeutic treatments. Especially lymphomas and leukemias, which are tumors of blood cells, successfully treatable up to 80%. However, most often solid tumors are highly resistant to standard treatments, especially if detected in advanced stages. A new family of drugs that give the immune system’s ability to kill tumor cells has succeeded in eliminating cancer patients with metastases who had remained without any other treatment option. These new drugs are the “most important in cancer treatment” since the arrival of calls molecular therapies fifteen years progress. This new innovative treatment, immunotherapy, is a method in which have been used proteins derived from tumors or tumor DNA mixed with adjuvants in order to generate an immune response against the tumor. The main strategy is to combine drugs to prevent the tumor develops resistance to treatment. They have also been used suppressive molecules regulation, thereby triggering spontaneous responses against cancer, such as antibodies. Cellular immunotherapy, does not generate significant damage in patients, which is an important alternative for patients with various cancers, because it is the “new form of treatment” to deal with cancer. On the other hand patients in earlier stages of the disease, this is no metastasis, can be cured with this treatment or greatly reduce the chances of relapse. Most patients who respond to new immunotherapies do permanently.